% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Nagy:279194,
author = {Nagy, Tamas and Gonda, Xenia and Gezsi, Andras and Eszlari,
Nora and Hullam, Gabor and González-Colom, Rubèn and
Mäkinen, Hannu and Paajanen, Teemu and Torok, Dora and Gal,
Zsofia and Petschner, Peter and Cano, Isaac and Kuokkanen,
Mikko and Schmidt, Carsten O and Van der Auwera, Sandra and
Roca, Josep and Antal, Peter and Juhasz, Gabriella},
title = {{P}harmacological profiling of major depressive
disorder-related multimorbidity clusters.},
journal = {European neuropsychopharmacology},
volume = {96},
issn = {0924-977X},
address = {Amsterdam},
publisher = {Elsevier},
reportid = {DZNE-2025-00722},
pages = {71 - 83},
year = {2025},
abstract = {We previously identified seven distinct multimorbidity
clusters associated with major depressive disorder through a
comprehensive analysis of 1.2 million individuals of
multiple cohorts. These clusters, characterized by unique
clinical, genetic, and psychiatric and somatic illness risk
profiles, implicate divergent treatment pathways and disease
management strategies. This study aims to deepen the
understanding of these clusters by analyzing drug
prescriptions, evaluating the effectiveness of
antidepressant treatment strategies, and identifying
potential markers for personalized medicine. Utilizing drug
prescription data in the format of ATC codes, we performed
epidemiological assessments, including multimorbidity
(number of diseases), polypharmacy (number of chemical
substances), and drug burden (number of prescriptions)
analyses across the clusters. We applied linear regression
models to assess strength and predictive capability of
cluster membership on various metrics, and logistic
regression to explore associations with treatment-resistant
depression. We also quantified and visualized common
antidepressant treatment sequences within each cluster. Our
findings indicate significant variations in polypharmacy and
drug burden across clusters, with distinct patterns emerging
that correlate with the clusters' profiles. Clusters liable
to multimorbidity have higher drug burden, even after
correction for number of diseases. Furthermore, the three
clusters with higher risk for MDD showed different
antidepressant treatment profiles; two required
significantly more antidepressant prescriptions and had a
higher risk for TRD. The detailed pharmacological profiling
presented in this study not only corroborates the initial
cluster definitions but also enhances our predictive
capabilities for treatment outcomes in MDD. By linking
pharmacological data with comorbidity profiles, we pave the
way for targeted therapeutic interventions.},
keywords = {Humans / Depressive Disorder, Major: drug therapy /
Depressive Disorder, Major: epidemiology / Antidepressive
Agents: therapeutic use / Multimorbidity / Male /
Polypharmacy / Female / Middle Aged / Cluster Analysis /
Adult / Aged / Antidepressants (Other) / Major depressive
disorder (Other) / Multimorbidity (Other) / Pharmacology
(Other) / Antidepressive Agents (NLM Chemicals)},
cin = {AG Grabe},
ddc = {610},
cid = {I:(DE-2719)5000001},
pnm = {353 - Clinical and Health Care Research (POF4-353)},
pid = {G:(DE-HGF)POF4-353},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:40483774},
doi = {10.1016/j.euroneuro.2025.05.007},
url = {https://pub.dzne.de/record/279194},
}